FDA Grants Fast Track Designation to NurOwn
The FDA has designated BrainStorm Cell Therapeutics' NurOwn as a "Fast Track" produce for the treatment of ALS. The FDA's Fast Track program ia designed to expedite the review of drugs and biologics intended to treat serious conditions and meet unmet medical needs through increased meetings and written communications with the FDA. A Phase 2 clinical trial of NurOwn is still recruiting participants. For more info on this trial: See ALS-TDI: NurOwn
Cytokinetics' Tirasemtiv Update
Cytokinetics provided a program update relating to tirasemtiv stating that it has concluded that effects obverved on Slow Vital Capacity in ALS patients treated with tirasemtiv are robust and potentically clinically meaningful. Cytokinetics believes the data supports a Phase 3 clinical trial that could begin in 2015. For more info: ALS-TDI: Tirasemtiv
Have you been seeing information on Facebook and other social media regarding Ubiquilin-2? The study referred to in those articles was published back in 2011! To see the original story, see the ALS-TDI: Ubiquilin-2
Weather and MDA
If you are impacted by severe weather and need MDA services -- including help repairing or replacing durable medical equipment that's been damaged by a storm or information about local groups offering emergency assistance and/or shelter, contact MDA by calling (800) 572-1717 or emailing firstname.lastname@example.org.
Individuals affected by ALS are at an increased risk of serious and possibly life-threatening complications from the flu, so it's important to stay informed and take steps to protect themselves and their families.
Mitophagy Pathway Links ALS and Parkinson's Disease
Researchers have linked genes for ALS and Parkinson's Disease in the same pathway, a cellular methanism to degrade decrepit mitochondria. For more info, see The ALS Forum
ALS Registry Findings
The data is derived from four nationwide administrative databases and a self-reporting web portal that were integrated into a single registry. In addition to serving as a comprehensive and systematic resource on the current state of ALS, the registry could potentially provide a large dataset for environmental risk analysis, if the data use and privacy constraints are resolved. To read more about this valuable new resource and the potential collaborations surrounding it, see The ALS Forum